JPH01132514A - Stable vitamin complex freeze-dried pharaceutical - Google Patents
Stable vitamin complex freeze-dried pharaceuticalInfo
- Publication number
- JPH01132514A JPH01132514A JP28853487A JP28853487A JPH01132514A JP H01132514 A JPH01132514 A JP H01132514A JP 28853487 A JP28853487 A JP 28853487A JP 28853487 A JP28853487 A JP 28853487A JP H01132514 A JPH01132514 A JP H01132514A
- Authority
- JP
- Japan
- Prior art keywords
- vitamins
- vitamin
- acid
- soluble
- basic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940088594 vitamin Drugs 0.000 title claims abstract description 44
- 229930003231 vitamin Natural products 0.000 title claims abstract description 44
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 44
- 239000011782 vitamin Substances 0.000 title claims abstract description 44
- 150000003722 vitamin derivatives Chemical class 0.000 title description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 4
- -1 inorganic acid salt Chemical class 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract description 3
- 229960000304 folic acid Drugs 0.000 abstract description 3
- 235000019152 folic acid Nutrition 0.000 abstract description 3
- 239000011724 folic acid Substances 0.000 abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 abstract description 3
- 229940055726 pantothenic acid Drugs 0.000 abstract description 3
- 235000019161 pantothenic acid Nutrition 0.000 abstract description 3
- 239000011713 pantothenic acid Substances 0.000 abstract description 3
- 235000019155 vitamin A Nutrition 0.000 abstract description 3
- 239000011719 vitamin A Substances 0.000 abstract description 3
- 239000004475 Arginine Substances 0.000 abstract description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004472 Lysine Substances 0.000 abstract description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract description 2
- 229930003268 Vitamin C Natural products 0.000 abstract description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002685 biotin Drugs 0.000 abstract description 2
- 235000020958 biotin Nutrition 0.000 abstract description 2
- 239000011616 biotin Substances 0.000 abstract description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 2
- 235000001968 nicotinic acid Nutrition 0.000 abstract description 2
- 239000011664 nicotinic acid Substances 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 235000021317 phosphate Nutrition 0.000 abstract description 2
- 235000019154 vitamin C Nutrition 0.000 abstract description 2
- 239000011718 vitamin C Substances 0.000 abstract description 2
- 235000019166 vitamin D Nutrition 0.000 abstract description 2
- 239000011710 vitamin D Substances 0.000 abstract description 2
- 235000019165 vitamin E Nutrition 0.000 abstract description 2
- 239000011709 vitamin E Substances 0.000 abstract description 2
- 235000019168 vitamin K Nutrition 0.000 abstract description 2
- 239000011712 vitamin K Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101150104365 Tomt gene Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000020772 multivitamin supplement Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
は
本発明内子術後等の栄養経口摂取不能の患者に適用する
高カロリー輸液に添り口するのに適した総合ビタミン凍
結乾燥製剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a lyophilized multivitamin preparation suitable for use as a sprig to high-calorie infusions applied to patients who are unable to take nutritional supplements orally, such as after internal eczema surgery.
近年、手術後等における栄養の経口摂取不能患者に対す
る栄養管理は経中心静脈栄養による高カロリー輸液療法
の発達に伴って飛躍的に向上し、この高カロリー輸液中
に各種の必須ビタミンを添加することも常識化されつつ
ある。In recent years, nutritional management for patients who are unable to take nutrients orally after surgery, etc. has improved dramatically with the development of high-calorie infusion therapy using central parenteral nutrition, and various essential vitamins have been added to this high-calorie infusion. is also becoming commonplace.
このために、高カロリー輸液に添加される総合ビタミン
與剤も様々な形態で開発されている。To this end, various forms of multivitamin supplements have been developed to be added to high-calorie infusions.
この総合ビタミンの製剤化において必要とされる性能と
して、型剤中のビタミンが有効かつ安全に人体に投与さ
れるために、製造してから使用するまでの市場流通にお
ける安定性並びにビタミンを添加した高カロリー輸液の
調型の際の細菌汚染をできる限り少なくするために使用
時の簡便性が重要である。ビタミンにはそれ自身不安定
なものが多くかつビタミン同士を配合したときに更に不
安定となる組合わせが多くあることから、総合ビタミン
はこれらのビタミン同士の配合安定性を考慮して幾つか
の容器に分けて製剤化することが行われている(特開昭
56−77222、特開昭58−116413)。In order for the vitamins in the mold to be effectively and safely administered to the human body, the required performance in formulating this multivitamin is stability during market distribution from manufacture to use, as well as the addition of vitamins. Convenience in use is important in order to minimize bacterial contamination during the preparation of high-calorie infusions. Many vitamins are unstable on their own, and there are many combinations that become even more unstable when they are combined with each other. The formulation is divided into containers and formulated (Japanese Patent Application Laid-open Nos. 56-77222 and 1982-116413).
しかしながら、使用時の簡便性の向上のためには、層剤
の容器数を出来るだけ少なくすることが望ましく、配合
安定性の良好な総合ビタミン剤の開発が期待されている
。However, in order to improve the ease of use, it is desirable to reduce the number of containers for the layered agent as much as possible, and the development of multivitamin preparations with good formulation stability is expected.
そこで、本発明者らは、総合ビタミン裂剤の安定化をは
かる目的で鋭意研究した結果、安定剤として塩基性アミ
ノ酸を使用すると総合ビタミン中のビタミン含量の低下
が押さえられることを見い出した。As a result of intensive research aimed at stabilizing multivitamin cleavage agents, the present inventors discovered that the use of basic amino acids as stabilizers suppresses the decrease in vitamin content in multivitamins.
本発明は上記知見に基づき完成されたものである。9種
の水溶性必須ビタミンとしてはビタミンBll B2.
86.81゜1葉酸、ニコチン酸又はニコチン酸アミド
、パントテン酸又はパントテニールアルコール、ビオチ
ン及びビタミンCが挙げられる。またこれ等のビタミン
に適当な可溶化剤を加えた脂溶性ビタミンを加えても良
い。脂溶性ビタミンにはビタミンA、 D、 E及び又
はビタミンKが挙げられる。これ等のビタミンの配合量
に特に限定はないが、ヒトの1日の必要な摂取量を補え
る量に近い量をそれぞれ配合することが好ましい。それ
ぞれのビタミンの配合量の例としてはビタミン821
10 ■、 ビタミンB61−10mg、パントテン酸
5−25rr@、ビタミンCC50−250ff1.
ビタミyB、1−10”’g、 ビタミンB121
30μg1葉酸100−1000μg1ピオチン20−
300μg1ニコチン酸10−50■、ビタミンA20
00−5000IU、ビタミンD200−1000IU
、ビタミンE5−20IU、ビタミンI(0,2−1o
譚の割合で配合されていることが望ましい。The present invention has been completed based on the above findings. The nine water-soluble essential vitamins include vitamin Bll B2.
86.81°1 Folic acid, nicotinic acid or nicotinamide, pantothenic acid or pantothenyl alcohol, biotin and vitamin C. Furthermore, fat-soluble vitamins obtained by adding a suitable solubilizer to these vitamins may be added. Fat-soluble vitamins include vitamins A, D, E and/or vitamin K. Although there are no particular limitations on the amounts of these vitamins, it is preferable to mix them in amounts that are close to the amount that can supplement the daily intake of humans. An example of the amount of each vitamin is vitamin 821.
10 ■, Vitamin B61-10mg, pantothenic acid 5-25rr@, vitamin CC50-250ff1.
Vitamin YB, 1-10”'g, Vitamin B121
30 μg 1 folic acid 100-1000 μg 1 piotin 20-
300 μg 1 nicotinic acid 10-50 ■, vitamin A 20
00-5000IU, vitamin D200-1000IU
, vitamin E5-20IU, vitamin I (0,2-1o
It is desirable that it be blended at the same ratio as Tan.
その配合量の具体例を表1に示す。Specific examples of the blending amounts are shown in Table 1.
表1 総合ビタミン剤のビタミン成分と配合量の倒木発
明で使用する塩基性アミノ酸としては例えばヒスチジン
、アルギニン、リジンなどがあげられる。Table 1: Falling Tree of Vitamin Components and Amounts of Multivitamin Preparations Examples of the basic amino acids used in the invention include histidine, arginine, and lysine.
又、塩基性アミノ酸の塩酸塩、硫酸塩、リン酸塩などの
無機酸との塩も利用しうる。これらの塩基性アミノ酸も
しくはそれと無機酸との塩は単独で用いてもよく、又、
2種以上併用してもよい。In addition, salts of basic amino acids with inorganic acids such as hydrochlorides, sulfates, and phosphates can also be used. These basic amino acids or their salts with inorganic acids may be used alone, or
Two or more types may be used in combination.
塩基性アミノ酸の使用量は配合するビタミンの全量に対
し、約7−約150 w/w%、好ましくは約20−約
100 w/w%程度がよい。The amount of basic amino acids to be used is about 7 to about 150 w/w%, preferably about 20 to about 100 w/w%, based on the total amount of vitamins to be mixed.
更に、凍結乾燥裂剤とする為に賦形剤を加えても良い。Furthermore, excipients may be added to form a freeze-dried cleaving agent.
賦形剤としては、マンニトールなどの糖アルコール、乳
糖、マルトース等の単糖、少糖類、コンドロイチン硫酸
、デキストラン等の高分子類があげられる。賦形剤を使
用する場合その使用量は配合ビタミン全量に対し、01
〜3倍、好ましくは0.3〜2.5倍用いるのがよい。Excipients include sugar alcohols such as mannitol, monosaccharides such as lactose and maltose, oligosaccharides, and polymers such as chondroitin sulfate and dextran. If excipients are used, the amount used should be 0.01% of the total amount of combined vitamins.
It is good to use up to 3 times, preferably 0.3 to 2.5 times.
また脂溶性ビタミンを添加する場合は可溶化剤を用いる
必要があり、例えばポリソルベート80などのポリオキ
シエチレンンルビタン脂肪酸エステルを用いることがで
きる。用いる可溶化剤の量は脂溶性ビタミンの3〜10
倍を用いることにより、凍結乾燥粘剤の再溶解時に澄明
な溶液を得ることが出来る。Further, when adding fat-soluble vitamins, it is necessary to use a solubilizer, and for example, polyoxyethylene rubitan fatty acid ester such as polysorbate 80 can be used. The amount of solubilizer used is 3-10% of the fat-soluble vitamin.
By using double the amount, a clear solution can be obtained upon re-dissolving the lyophilized sticky agent.
本発明の層剤は常法の注射剤の製造方法によることがで
きる。すなわち、水溶性ビタミンは注射用の蒸留水に溶
解し、更に本発明による安定剤を溶解した後、水酸化ナ
トリウム等のpI−1調整剤を用いてpH4,5〜6.
5に調整して薬液を得る。この薬液は容器に小分けした
後、凍結乾燥することにより裂創を得る。更に脂溶性ビ
タミンを加える場合は、前記の薬液に更に界面活性剤で
可溶化した脂溶性ビタミンの水溶液を加えたものについ
て容器に小分けし凍結乾燥すれば良い。薬液中の固型分
の濃度は特に限定はないが、ビタミンや賦形剤の溶解性
と凍結乾燥した裂創の溶解性並びに凍結乾燥の難易性と
効率を考慮して選択される。すなわち、濃度が濃すぎる
場合には薬液調製時の溶解性及び凍結乾燥時の結晶析出
による再溶解性の低下を起こし、また薄すぎる場合には
除去すべき水分が勿いために乾燥効率の低下をまねく。The layer agent of the present invention can be prepared by a conventional method for producing an injection. That is, water-soluble vitamins are dissolved in distilled water for injection, and after further dissolving the stabilizer according to the present invention, the pH is adjusted to pH 4.5-6 using a pI-1 adjusting agent such as sodium hydroxide.
5 to obtain a chemical solution. This drug solution is divided into containers and then freeze-dried to obtain lacerated wounds. If fat-soluble vitamins are to be added, an aqueous solution of fat-soluble vitamins solubilized with a surfactant may be added to the above-mentioned drug solution, and the resulting mixture may be divided into containers and freeze-dried. The concentration of the solid content in the drug solution is not particularly limited, but is selected in consideration of the solubility of vitamins and excipients, the solubility of freeze-dried lacerations, and the difficulty and efficiency of freeze-drying. In other words, if the concentration is too high, the solubility during preparation of the drug solution and the resolubility due to crystal precipitation during freeze-drying will decrease, and if the concentration is too low, the drying efficiency will decrease due to the lack of water to be removed. Maneku.
本発明におけるビタミン配合量の範囲では固型分が1〜
tomt中に含まれることが望ましい。In the range of vitamin compounding amount in the present invention, the solid content is 1 to 1.
It is desirable to include it in tomt.
本発明により調製された試料群及び対照として安定化剤
を添加せずに調製した試料を50℃の条件下に10日保
存後、試料中のビタミンの含量を測定し、残存率を求め
た。試料は後記実施例1.2の組成のものを用いた。対
照として、実施例1の製剤から安定剤を除いたものを用
いた。結果を表2に示す。After storing the sample group prepared according to the present invention and a sample prepared without adding a stabilizer as a control at 50° C. for 10 days, the content of vitamins in the samples was measured and the residual rate was determined. The sample used had the composition shown in Example 1.2 below. As a control, the formulation of Example 1 without the stabilizer was used. The results are shown in Table 2.
この表から明らかなように、本発明の製剤は対照例と比
較してビタミンの安定性は向上しておす、特にジアノコ
バラミンの安定性が大巾に向上している。As is clear from this table, the formulation of the present invention has improved vitamin stability compared to the control example, and in particular, the stability of dianocobalamin has been greatly improved.
表2
以上から明らかなように本発明によると一つの容器でも
各種ビタミンの含量低下を押さえた安定な総合ビタミン
凍結乾燥製剤を得ることができる。Table 2 As is clear from the above, according to the present invention, a stable lyophilized multivitamin preparation with reduced content of various vitamins can be obtained even in a single container.
実施例1゜
表1に示すビタミンの配合量に従い水溶性ビタミンを注
射用蒸留水に溶解する。この溶液に安定剤としてヒスチ
ジン塩酸塩(1水和物)を50■添加して溶解する。ま
た脂溶性ビタミンをポリソルベート8060■を用いて
注射用蒸留水中に可溶化して水溶液となす。この両液を
混合し、水酸化ナトリウムを用いてpHを約5.0に調
整し、全量を2 mlとした。得られた薬液をバイアル
に充填し、凍結乾燥した後ゴム栓をして本発明品を得た
。Example 1 Water-soluble vitamins were dissolved in distilled water for injection according to the amounts of vitamins shown in Table 1. To this solution, 50 μm of histidine hydrochloride (monohydrate) was added as a stabilizer and dissolved. In addition, fat-soluble vitamins are solubilized in distilled water for injection using polysorbate 8060 to form an aqueous solution. These two solutions were mixed, and the pH was adjusted to about 5.0 using sodium hydroxide, so that the total volume was 2 ml. The obtained drug solution was filled into a vial, freeze-dried, and then sealed with a rubber stopper to obtain a product of the present invention.
実施例2゜
実施例1において、ヒスチジン塩酸塩を50■のかわり
に100■、全量を3 mlとし、他は実施例1と同様
に操作して、本発明品を得た。Example 2 A product of the present invention was obtained by carrying out the same procedure as in Example 1, except that the amount of histidine hydrochloride was changed to 100 ml instead of 50 ml, and the total amount was 3 ml.
実施例3゜
実施例1において、ヒスチジン塩酸塩のかわりにアルギ
ニン塩酸塩、他は実施例1と同様に操作して、本発明品
を得た。Example 3 A product of the present invention was obtained in the same manner as in Example 1 except that arginine hydrochloride was used instead of histidine hydrochloride.
実施例4゜
実施例1において、ヒスチジン塩酸塩のかわりにリジン
塩酸塩とし、他は実施例1と同様に操作して対照品を得
た。Example 4 A control product was obtained in the same manner as in Example 1 except that lysine hydrochloride was used instead of histidine hydrochloride.
Claims (1)
ノ酸を含有することを特徴とする総合ビタミン凍結乾燥
製剤。A lyophilized multivitamin preparation characterized by containing at least nine water-soluble essential vitamins and basic amino acids.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62288534A JPH062664B2 (en) | 1987-11-17 | 1987-11-17 | Stable multivitamin freeze-dried preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62288534A JPH062664B2 (en) | 1987-11-17 | 1987-11-17 | Stable multivitamin freeze-dried preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01132514A true JPH01132514A (en) | 1989-05-25 |
JPH062664B2 JPH062664B2 (en) | 1994-01-12 |
Family
ID=17731484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62288534A Expired - Lifetime JPH062664B2 (en) | 1987-11-17 | 1987-11-17 | Stable multivitamin freeze-dried preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH062664B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005799A1 (en) * | 1991-09-24 | 1993-04-01 | Farmitalia Carlo Erba S.R.L. | Lyophilized stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
WO1998034623A1 (en) * | 1997-02-05 | 1998-08-13 | Kirin Beer Kabushiki Kaisha | Freeze-dried composition containing glycosphingolipid and process for producing the same |
US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
CN102068453A (en) * | 2009-11-23 | 2011-05-25 | 北京京卫信康医药科技发展有限公司 | Stable complex vitamin composite and preparation method thereof |
CN113368064A (en) * | 2021-06-08 | 2021-09-10 | 吉林津升制药有限公司 | Nicotinic acid freeze-dried powder and preparation method thereof |
-
1987
- 1987-11-17 JP JP62288534A patent/JPH062664B2/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993005799A1 (en) * | 1991-09-24 | 1993-04-01 | Farmitalia Carlo Erba S.R.L. | Lyophilized stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
WO1998034623A1 (en) * | 1997-02-05 | 1998-08-13 | Kirin Beer Kabushiki Kaisha | Freeze-dried composition containing glycosphingolipid and process for producing the same |
US6417167B1 (en) | 1997-02-05 | 2002-07-09 | Kirin Beer Kabushiki Kaisha | Lyophilized compositions containing shingoglycolipid and process for preparing them |
CN102068453A (en) * | 2009-11-23 | 2011-05-25 | 北京京卫信康医药科技发展有限公司 | Stable complex vitamin composite and preparation method thereof |
CN113368064A (en) * | 2021-06-08 | 2021-09-10 | 吉林津升制药有限公司 | Nicotinic acid freeze-dried powder and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JPH062664B2 (en) | 1994-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6802879B2 (en) | Treatment of erectile dysfunction and other indications | |
CA2234140C (en) | Stable freeze-dried pharmaceutical formulation | |
EP0650354B1 (en) | Solid and liquid solutions of drugs which are not readily soluble in water | |
JP3031570B2 (en) | Preparations containing stabilized gonadotropin | |
EP2373346B1 (en) | Ibuprofen for topical administration | |
CN102068453B (en) | Stable complex vitamin composition and preparation method thereof | |
AU2003267131A1 (en) | Formulation for lipophilic agents | |
JPH07509719A (en) | Human growth hormone aqueous preparation | |
JP2002502811A (en) | Propofol compositions containing sulfites | |
KR20120106933A (en) | Topical composition containing ibuprofen | |
MX2007004490A (en) | Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent. | |
CN112789059A (en) | Use of amino acid nutrients and pharmaceutical compositions containing same | |
JP2014533251A (en) | Melatonin-based solutions and powders for their production | |
JP2017514924A (en) | Preparation of cyclophosphamide liquid concentrate | |
CN110464846B (en) | Meloxicam composition, preparation method and application thereof | |
EP2704596B1 (en) | Oral compositions comprising creatine | |
CN112402371B (en) | Rudesiwei injection and preparation method thereof | |
US20160000716A1 (en) | Method of treating vitamin b12 deficiency | |
JPH01132514A (en) | Stable vitamin complex freeze-dried pharaceutical | |
SK2092002A3 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
JP2529605B2 (en) | Immunostimulant | |
CN108606955A (en) | The Pharmaceutical composition and preparation method thereof of trainingization Xihai sea horse peptide | |
CN102357081A (en) | Composite fat-soluble vitamin freeze-dried powder injection and preparation method thereof | |
JPS63310815A (en) | Stable freeze-dried vitamin complex preparation | |
JP3155312B2 (en) | Stable intravenous multivitamin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |